A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma. The discovery of effective therapy for NAFLD is an essential unmet need. Angiopoietin-like protein 3 (ANGPTL3), a...

Full description

Bibliographic Details
Main Authors: Xiaozhi Hu, Jiajun Fan, Qianqian Ma, Lei Han, Zhonglian Cao, Caili Xu, Jingyun Luan, Guangjun Jing, Yanyang Nan, Tao Wu, Yuting Zhang, Hanqi Wang, Yuanzhen Zhang, Dianwen Ju
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Journal of Nanobiotechnology
Subjects:
ANGPTL3
Nanobody
Lipid-reducing
Hypercholesterolemia
NAFLD
Online Access:https://doi.org/10.1186/s12951-022-01456-z

Internet

https://doi.org/10.1186/s12951-022-01456-z

Similar Items